Mammalian Cell Culture CDMO Market Size, Share, Forecast Report 2026 to 2035

What is Mammalian Cell Culture CDMO Market  Size? 

Global Mammalian Cell Culture CDMO Market is estimated to grow with a 11.5% CAGR during the forecast period for 2026 to 2035.

Mammalian Cell Culture CDMO Market Size, Share & Trends Analysis Distribution by Service Type (Development Services, Cell Line Development, Process Development, Analytical and Formulation Development, Clinical GMP Manufacturing, Early-Phase Clinical Manufacturing, Late-Phase Clinical Manufacturing, Commercial GMP Manufacturing), by Molecule Type (Monoclonal Antibodies, Bispecific and Multispecific Antibodies, Fc-Fusion Proteins and Other Recombinant Proteins, Other Mammalian-Expressed Biologics), By Expression System (CHO Cell Lines, Murine Myeloma Cell Lines, HEK293 and Other Mammalian Cell Lines), by End User, by Bioreactor Technology) and Segment Forecasts, 2026 to 2035.

Mammalian cell culture technology encompasses the use of mammalian expression systems to develop and manufacture complex biopharmaceutical molecules that require sophisticated cellular machinery for appropriate protein folding, post-translational modification, and biological activity. It is a fundamental platform in modern biopharmaceutical manufacturing, particularly for the production of monoclonal antibodies, recombinant proteins, therapeutic antibodies, fusion proteins, biosimilars, and other complex biologics. Common mammalian expression systems include Chinese Hamster Ovary (CHO) cells, Human Embryonic Kidney (HEK293) cells, murine myeloma cells, and other engineered mammalian cell lines.

The mammalian cell culture CDMO market encompasses outsourced development and manufacturing services that support the design, optimization, scale-up, and production of mammalian cell culture-based biopharmaceuticals. These services span multiple stages of the biopharmaceutical manufacturing lifecycle, including cell line development, cell banking, process development and optimization, upstream processing, bioreactor-based cell culture, downstream purification, analytical development and testing, formulation, and GMP-compliant manufacturing. Service capabilities may extend from early-stage and preclinical development through clinical manufacturing and commercial-scale production.

Mammalian cell culture CDMOs provide pharmaceutical and biotechnology companies with access to specialized manufacturing infrastructure, technical expertise, advanced bioreactor systems, process development capabilities, and regulatory-compliant production facilities without requiring equivalent investments in internal manufacturing capacity. Their services support a range of molecules and development stages, from early research and process characterization to clinical-stage manufacturing and commercial supply. Manufacturing platforms may incorporate single-use bioreactors, high-throughput process development, automated process control, advanced analytical technologies, and scalable downstream purification systems to improve process consistency and manufacturing efficiency.
The market serves a diverse customer base comprising large pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, virtual and small-to-medium-sized biopharma firms, and academic or research institutions. The increasing complexity of biologic molecules, growing development pipelines, demand for flexible manufacturing capacity, and need for scalable and compliant production infrastructure are strengthening the role of mammalian cell culture CDMOs across the biopharmaceutical value chain. As biologics progress from discovery and preclinical development through clinical evaluation and commercial manufacturing, CDMOs increasingly provide integrated capabilities spanning development, technology transfer, scale-up, and GMP production.

Competitive Landscape

Which are the Leading Players in the Mammalian Cell Culture CDMO Market?

• Lonza Group AG
• Samsung Biologics Co., Ltd.
• WuXi Biologics (Cayman) Inc.
• FUJIFILM Biotechnologies (FUJIFILM Corporation)
• Boehringer Ingelheim BioXcellence
• Thermo Fisher Scientific Inc. (Patheon Pharma Services)
• AGC Biologics (AGC Inc.)
• Catalent, Inc. (Novo Holdings A/S)
• Rentschler Biopharma SE
• KBI Biopharma, Inc. (JSR Life Sciences)
• Just – Evotec Biologics, Inc.
• Lotte Biologics Co., Ltd.
• Celltrion, Inc. (Celltrion BioSolutions)
• Syngene International Ltd.
• Avid Bioservices, Inc.
• Abzena Ltd.
• Celonic Group
• Rezon Bio
• mAbxience (Fresenius Kabi)
• AbbVie Contract Manufacturing
• Pfizer CentreOne
• ProBio (GenScript Biotech Corporation)
• ProBioGen AG
• 3P Biovian
• Chime Biologics
• MabPlex International
• Binex Co., Ltd.
• Kemwell Biopharma
• Aurigene Pharmaceutical Services
• Enzene Biosciences
• Mabion S.A.
• Northway Biotech
• Cytovance Biologics
• National Resilience, Inc.
• Tanvex BioPharma
• Sartorius AG
• Cytiva (Danaher Corporation)
• Merck KGaA (MilliporeSigma)
• Sandoz AG
• Polpharma Biologics
• Samsung Epis Holdings (Samsung Bioepis)
• Biocon Biologics Ltd.
• WuXi XDC Cayman Inc.
• Terumo Corporation
• Richter-Helm BioLogics
• Wacker Biotech
• Charles River Laboratories
• Eurofins BioPharma Product Testing

Market Dynamics

Driver

Growing Demand for Monoclonal Antibodies and Complex Biologics

Demand for monoclonal antibodies, recombinant proteins, biosimilars, and other complex biologics is fueling growth in the mammalian cell culture CDMO market. Companies often use mammalian expression systems, especially Chinese Hamster Ovary (CHO) cells, because they can produce complex proteins with the right folding and modifications. As pharmaceutical and biotech firms grow their biologics pipelines, they need more specialized cell culture development and manufacturing. The high cost of building and running in-house facilities is also pushing companies to outsource production to CDMOs, which provide advanced bioreactor setups, technical know-how, and GMP-compliant manufacturing.

Restrain/Challenge

High Manufacturing Costs and Complexity of Mammalian Cell Culture Processes

One of the main challenges in the mammalian cell culture CDMO market is the high cost and technical complexity of making biologics with mammalian expression systems. To keep cells growing well and producing quality products, manufacturers need strict controls and specialized equipment. The process also needs costly media, supplements, bioreactors, and purification steps, which raise production costs. Scaling up while keeping batches consistent and meeting strict GMP and regulatory standards adds more complexity. These issues can limit capacity and increase costs for CDMOs, especially when working with smaller biotech companies and early-stage clinical programs.

Drug Substance Manufacturing Segment is Expected to Drive the Mammalian Cell Culture CDMO Market

The drug substance manufacturing segment is expected to make up a large part of the mammalian cell culture CDMO market, mainly because more companies are outsourcing the production of monoclonal antibodies, recombinant proteins, and other biologics. Making drug substances involves large-scale cell culture, processing, harvesting, and purification to create active pharmaceutical ingredients. More pharmaceutical and biotech companies are turning to CDMOs for these tasks since they need specialized equipment, expertise, and regulatory know-how. As more biologics move through clinical trials and reach the market, the need for flexible and reliable GMP-compliant drug substance manufacturing keeps growing.

Commercial-Scale GMP Manufacturing Segment is Expected to Witness Strong Growth in the Mammalian Cell Culture CDMO Market

The commercial-scale GMP manufacturing segment is set to grow as more biologic drug candidates move through clinical trials and get regulatory approval. As more monoclonal antibodies, biosimilars, and other therapeutic proteins become available, there is greater demand for large-scale manufacturing that delivers consistent quality and supply. Building commercial-scale mammalian cell culture facilities takes a lot of investment, advanced bioreactors, and regulatory expertise, so many companies choose to work with established CDMOs. Investments in single-use bioreactors, automation, and process improvements are also making production more flexible and helping expand commercial manufacturing services.

Why North America Led the Mammalian Cell Culture CDMO Market?

North America is expected to lead the mammalian cell culture CDMO market because of its strong biopharmaceutical industry, active biologics research, and major contract manufacturing organizations. The region has seen big investments in biologics, a large pipeline of monoclonal antibodies and recombinant proteins, and rising demand for outsourced manufacturing.

Companies like Lonza Group AG, FUJIFILM Biotechnologies, AGC Biologics, and KBI Biopharma have set up advanced manufacturing operations to support pharma and biotech clients. New biotech firms, established drug makers, and top research institutions also add to the customer base for outsourced cell culture services. Ongoing investments in manufacturing capacity, single-use bioreactors, and process improvements are making North America even stronger in this market.

Key Development:

•    In May 2026, Samsung Biologics Co., Ltd. introduced updated cell culture material generation strategies designed to accelerate biologics development. Its approach combines cell line development with optimized material generation, reducing material delivery timelines from approximately 7.5 weeks to 5 weeks and increasing material output by more than 20 times compared with traditional workflows. The development supports faster process evaluation and improved manufacturing readiness for complex biologics.

•    In May 2026, 3PBIOVIAN expanded its mammalian cell culture manufacturing capacity by installing an additional 2,000-liter single-use bioreactor. The investment strengthens its recombinant protein manufacturing platform, which supports development and GMP production from small-scale operations to commercial-scale drug substance manufacturing.

Mammalian Cell Culture CDMO Market Report Scope: